US Specialty Formulations LLC, Allentown, PA
Is US Specialty Formulations LLC registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names US Specialty Formulations LLC in Allentown, PA, first registered Jan 31, 2014 and most recently registered Dec 3, 2025.
Does US Specialty Formulations LLC hold a Pennsylvania pharmacy license?
State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page. The Delaware Division of Professional Regulation also lists nonresident license AD-0000034 for US Specialty Formulations, LLC, ALLENTOWN, PA, status Active, as of Nov 10, 2026.
Has US Specialty Formulations LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 26, 2023) for US Specialty Formulations LLC. State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- US Specialty Formulations LLC
- Location
- Allentown, PA
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as US Specialty Formulations LLC
- Form 483s on FDA’s actions page
- 3
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Jan 14, 2026
- FDA Data Dashboard inspections
- 7 inspections: 5 OAI, 1 VAI, 1 NAI; 6 published Form 483s
- Form 483 text on this page
- 4 Form 483s, 42 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as US Specialty Formulations LLC, a 503B facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Jan 14, 2026 | Form 483 | 483 Issued 01/14/2026 | fda.gov |
| Jul 2, 2024 | Form 483 | 483 Issued 07/02/2024 | FDA copy (archived) |
| Jul 26, 2023 | Warning letter | Warning Letter (07/26/2023) | FDA copy (archived) |
| Apr 26, 2022 | Amended Form 483 | Amended 483 Issued 04/26/2022 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists US Specialty Formulations LLC, Allentown, PA (FEI number 3010680515), matched to this page by exact name, city and state. It lists 7 inspections: 5 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 26, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010680515 | 1265449 |
| Jul 2, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010680515 | 1243882 |
| Apr 26, 2022 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs): Official Action Indicated (OAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Official Action Indicated (OAI) | 3010680515 | 1167934 |
| Jul 23, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010680515 | 1097950 |
| Aug 29, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010680515 | 1023411 |
| May 29, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010680515 | 928445 |
| Mar 18, 2014 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3010680515 | 871574 |
Form 483s FDA has published for this site
- Jan 14, 2026: Form 483 to US Specialty Formulations LLC, published Feb 3, 2026. fda.gov
- Jul 2, 2024: Form 483 to US Specialty Formulations LLC, published Nov 12, 2024. fda.gov
- Apr 26, 2022: Form 483 to US Specialty Formulations LLC, published Sep 26, 2022. fda.gov
- Jul 23, 2019: Form 483 to US Specialty Formulations LLC, published Sep 30, 2019. fda.gov
- Oct 25, 2017: Form 483 to US Specialty Formulations LLC, published Jan 17, 2024. fda.gov
- Jul 17, 2015: Form 483 to US Specialty Formulations LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 42 numbered observations in all, across 4 inspections ending Aug 29, 2017 to Jul 2, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jun 17, 2024 to Jul 2, 2024: 7 observations
- Firm on the cover
- US Specialty Formulations LLC, 1401 S Albert St, Allentown, PA 18103- 4141
- Establishment type on the cover
- Out sourcing Facility
- FDA district office on the cover
- Philadelphia, PA 19106
- Matched to this page by
- firm name, city and state on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The quality control unit lacks the responsibility and authority to approve and reject all components, drng product containers, closures, in process materials, packaging material, labeling and drng products.
Specifically,
a.You failed to determine the potency of your finished San acenia Purpurea 0. l 7g/ml diug product.
You did not perfo1m or conduct testing prior to release of your diu g product to verifv the strength you claim on your product label of 0 .17 g/ml. You have released approximately [(b) ( 4 ~ vials ofSan acenia Purpurea 0. l 7g/ml injection di11g product since June 2022. b.You failed to dete1mine the potency of your finished San acenia Purpurea Bulk Distillate. You did not perfo1m or conduct testing prior to release ofyour diu g product to verify the strength you claim on your finished diu g product label of0.17 g/ml. You have released approximatel{j lots of the San acenia iPmpuya Bulk Distillate which had been used in the production and release of approximately (t>) (4) vials of Sa1rncenia Purpurea 0 .17 g/mL injection diu g product since June 2022.
Observation 2
Laborato1y controls do not include dete1mination of confo1mance to appropriate written specifications for the acceptance ofeach lot within each shipment of components used in the manufacture, processing, packing, or holding ofdi11g products.
Specifically,
b.The receiving process for Sanacenia Pmpurea plant consists of weighing and visual inspection for odor and color, DNA sequencing and genetic identifications. You do not perfo1m testing of incoming Sanacenia Pmpurea plant leaves for residual pesticide per USP <561>, inicrobial testing, elemental impurities, adventitious toxins such as aflatoxins or cai·cinogenicity. Additionally, you do not test the Sanacenia bulk distillate or the Sanacenia Pmpurea 0. l 7g/ml injection finished m11g product for adventitious toxins such as aflatoxins and cai·cinogenicity.
Observation 3
The written stability program for mug products does not include reliable, meaningful and specific test methods.
Specifically,
a.Your established testing specification for Sanacenia Pmpurea 0 .17 g/ml injection m11g product failed to provide adequate stability data to suppo1i the product for confo1mance to any established specification throughout the life cycle and to suppo1i the labeled 12-month expiiy date. b.The test methods used to dete1mine the stability ofSairncenia Pmpurea 0. l 7g/ml finished m11g product ru.·e not stability indicating in that they ru.·e not capable of identifying potential degradants and impurities in the Sairncenia Pmpurea Bulk Distillate or the finished m11g product, c.You failed to provide adequate data to suppo1i your 12 months retest date for the Bulk Sairncenia
Observation 4
Testing and release ofm11g product for distribution do not include appropriate laborato1y dete1mination of satisfacto1y confo1mance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically,
□ You have compounded and released approximately Obatches of Sanacenia Pmpurea Bulle Distillate and approximatel[J~(6) (4),~ vials of Sanacenia Pmpurea 0.17 g/ml injection finished mug product to include Lot 6 (4) to the US market since 2022. 7
DY ou do not have test method designed to dete1mine the potency or concentration of an active
ingredient and the constituents of your Bulle Sanacenia Distillate and Final mug product Sairncenia Pmpurea injection 0. l 7g/ml prior to release.
Observation 5
Procedures designed to prevent microbiological contamination of mug products pmpo1ting to be sterile are not followed.
Specifically,
a.After exiting the ISO 7 room to the ISO 8 room approximately 10 times: touching supplies,
cleaning and sanitizing the floor, measuring the air l?:1ticulates in suppo1t ISO 8 rooms, and documenting on the Production Record; Techniciat{:J failed to don new gloves adequately re-sanitize the same r o1es prior to transfeITing proauction materials to the ISO 5 Biological
4 Safety Cabinet BSC b) < For instance, on 06/1 9/2024, at 11 .52am : after exiting the ISO 7 room to the ISO 8 room multiple times, I observed Teclf '"'"'T take supplies from ISO 7 stainless steel table and place them directly into the BSC hood. He repeated the transfer of supplies directly to the BSC hood again at 11 :54 am. During the transfer of supplies, he only had one sterile glove donned since he entered the ISO 7 room and all throughout the compounding, capping operations for Sairncenia Purpurea 0.17 g/ml Injection Lot[{b) (4) I ...
Observation 6
Reserve samples from representative sample lots or batches of diug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
Specifically, you failed to perfo1m and document an annual visual examination of your retain samples of Sairncenia Purpurea 0. 17g/ml injection finished diug products for any evidence of deterioration.
Observation 7
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been ah-eady distributed.
Specifically, your visual inspection program for San acenia Purpurea 0.17g/ml injection finished mug products failed to include a process whereby critical defects to include paiiiculates observed during I 00 % visual inspected of your finished mug products ru.·e investigated and the source of the paiiiculates ru.·e detennined.
For examples during the I 00% visual inspection of the following but not limited lots of San acenia Pmpurea 0.17g/ml injection finished mug products: lots [(D) ~) I white paiiicles and dark pa1iicles were observed in some of the vials which were rejected. You have not conducted investigations to identify these paiiicles or characterized these paiiiculates found in these batches to detennine if they are intrinsic, extrinsic or inherent to the product.
Inspection Mar 21, 2022 to Apr 26, 2022: 17 observations
- Firm on the cover
- US Specialty Formulations LLC, 1401 S Albert St, Allentown, PA 18103-4141
- FEI number
- 3010680515
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- US Customhouse Rm 900 200 Chestnut St Philadelphi a, PA 19106
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency paiiiculate air filters under positive pressure.
Specifically, 1 <Redacted B4> aseptic vial filling and sealing operations performed within your ISO 5 classified biological safety cabinet BSC <Redacted B4> obstruct first pass HEPA filtered air in the critical zones over open vials and ooen stoppers. During the <Redacted B4> aseptic filling of 95% Ethanol for Injection, Lot Number: <Redacted B4> on 04/05/2022 we observed:
a. The design of your <Redacted B4> filling equipment, including the flexible tubing and barbed fitting used as a filling nozzle grasped by the technician during operation, causes the filling technician's fingers to obstruct first pass HEPA filtered air when positioned in close proximity (within 5 cm) above open vials as necessary to direct the flow of the drug product into vials.
b. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically:
L During our observation of <Redacted B4> aseptic filling of 95% Ethanol for Injection, Lot Number: .J on 04/05/2022 we observed objectionable practices that provide a route for contamination of finished drug product:
1. The filling technician working within the ISO 5 BSC <Redacted B4> places the filling tubing and barbed fitting used as a filling nozzle on nonsterile clean room wipes when filling is paused for actions including passing the tray of filled vials to the sealing operator and receiving new trays of vials for filling.
2 The filling technician working within the ISO 5 BSC <Redacted B4> receives vials and stoppers in wrapping <Redacted B4> with <Redacted B4> and handled in the ISO 7 classified Room <Redacted B4> by the support technician donned in non-sterile exam gloves. a. ...
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically:
I During our observation of <Redacted B4> aseptic filling of 95% Ethanol for Injection, Lot Number: <Redacted B4> on 04/05/2022 we observed that you use nonsterile clean room wipes inside the ISO 5 classified BSC <Redacted B4> for purposes to include:
a. Sanitization of BSC <Redacted B4> surfaces with sterile <Redacted B4> before production.
b. Resting the filling tubing and barbed fitting used as a filling nozzle on nonsterile clean room wipes when filling is paused.
c. Wiping the <Redacted B4> while <Redacted B4> the filling system.
2. Your procedure SOP # PR-0040 Cleaning of Classified Rooms in the <Redacted B4> Production Area, Effective Date: 09/03/2021 does not allow sufficient disinfectant <Redacted B4> contact time to achieve adequate levels of disinfection of the ceiling panels, ceiling grid, light fixtures, and HEPA filter diffusers. ...
Observation 4
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
AM ENDMENTl
Specifically:
Your surface and airborne viable monitoring program for aseptic filling operations is not designed and conducted to provide meaningful data to support the quality of your drug products intended to be sterile.
I . You have not established scientific justification for the environmental and personnel monitoring action limits set within your ISO 5 environment. Your response to the action level CFU provided in your procedure SOP# PR-0041 Environmental Monitoring Program, Effective Date: 08/06/2021 and action level <Redacted B4> CFU written in the Test Report permits personnel, surface, and air samples from within the critical zone of the ISO 5 classified biological safety cabinet BSC <Redacted B4> to yield microbial recoveries of 1 CFU ( colony forming unit) without investigation. For example:
a. ...
Observation 5
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the sterilization process.
Specifically:
I . An appropriate sterilization load monitor is not included with each drug product load intended for terminal sterilization. Your procedure SOP # EQ-0003 <Redacted B4> Operation Effective Date: 06/22/2021 requires use of a <Redacted B4> for only the <Redacted B4> in <Redacted B4> and <Redacted B4> for terminally sterilized drug products Medroxyprogesterone Acetate 150 mg/ml for injection and Sanacenia Purpurea 0.17 glml for injection.
2. You have not adequately validated the <Redacted B4> in <Redacted B4> and <Redacted B4> for load patterns <Redacted B4> containing <Redacted B4> (received <Redacted B4> and ready to sterilize) and the filling tubing sets used for <Redacted B4> aseptic filling of drug products B-Complex + Chromic Chloride 30 mL for injection and Ethanol for Injection 95% and terminally sterilized drug products Medroxyprogesterone Acetate 150 mg/ml for injection and Sanacenia Pupurea 0.17 g/ml for injection. ...
Observation 6
Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.
Specifically:
1. There were at least two unsealed loose ceiling tiles in the ISO 7 classified formulation/filling room <Redacted B4> which houses the ISO 5 classified biological safety cabinet BSC <Redacted B4>. One of the dislodged ceiling tiles was observed above and adjacent to the ISO 5 classified biological safety cabinet BSC <Redacted B4>
2. There were loose and dislocated pre filters on three out <Redacted B4> HEPA Filter/Fan units servicing your <Redacted B4> clean room suite that may affect the air volume and velocity/delivered from each unit and change conditions including the air balance certified during the last <Redacted B4> clean room certification performed on 08/26/2021. The <Redacted B4> clean room suite includes the ISO 7 classified formulation/filling room <Redacted B4> and the ISO 5 classified biological safety cabinet BSC <Redacted B4>.
3. ...
Observation 7
Routine calibration of automatic, mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.
Specifically:
You have not established a calibration program to include calibration of <Redacted B4>. You were unable to provide any evidence of calibration for the temperature and timing devices on <Redacted B4> used for sterilization of components including vial stoppers, equipment including filling tubing, and terminal sterilization of Medroxyprogesterone Acetate 150 mg/ml for injection and Sanacenia Purpurea 0 .17 g/ml for injection.
Observation 8
AMENDMENT l
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Specifically, you do not include quality control testing for sterility of your terminally sterilized drug products prior to release and you do not have adequate support for your program of parametric release for terminally sterilized drug products Medroxyprogesterone Acetate 150 mg/ml for injection and Sarcenia Purpurea 0 .17 g/ml for injection. An appropriate sterilization load monitor is not included with each drug product load intended for terminal sterilization.
Observation 9
Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.
Specifically, each lot of aseptically filled drug products B-Complex + Chromic Chloride 30 mL for injection and Ethanol for Injection 95% and terminally sterilized drug products Medroxyprogesterone Acetate 150 mg/ml for injection and Sanacenia Purpurea 0.17 g/ml for injection is not tested for container closure integrity prior to release.
Observation 10
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically:
1. You did not adequately evaluate products where actionable microbial contamination was recovered in the ISO 5 classified aseptic processing area during sampling associated with aseptic production. Your investigation Process Nonconformance No. 39 initiated for over action level <Redacted B4> CFU recovered from the bench top surface sample taken in the ISO 5 classified biological safety cabinet BSC <Redacted B4> and CFU from the gloved left hand (fingers) personnel sample after <Redacted B4> filling of Ethanol for Injection 95%, Lot # <Redacted B4>, Expiiy: 06/30/2023, was not completea and closed out before the batch was released on 02/03/2022 and the investigation remained open. Gram Variable Paenibacillus xylanexedens was identified on both samples and Sphingomonas yabuuchiea was identified on the bench top surface sample taken in the ISO 5 BSC <Redacted B4>.
AM ENDMENTl ...
Observation 11
AMENDMENTl
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically, you do not have test methods designed to determine the potency or concentration of each active ingredient prior to release of Sanacenia Purpurea 0 .1 7 g/ml for injection drug product.
This is a repeat observation from the previous FDA 483 list of observations issued on 07/23/2019.
Observation 12
The written stability program for drug products does not include meaningful and specific test methods.
Specifically:
I . You do not have stability indicating test methods for Sanacenia Purpurea 0.17 g/ml for injection drug product designed to test the product for conformance to any established specifications throughout its lifecycle and support the labeled 18-month expiry dating.
2. The expiration date for Medroxyprogesterone Acetate 150 mg/ml for injection is not based on sound scientific data. The expiration date o f 12 months as stated in QC-0074Fl is based on a stability report for Medroxyprogesterone Acetate 150 m5 m1 for injection lot <Redacted B4> released in September 2017. This stability report monitors vials at time point <Redacted B4> but only vial at the <Redacted B4> an <Redacted B4> month time points. The assay report form QC-0034.Fl, which records stability data for the product, contains an assay result for vial <Redacted B4> but vials and are crossed out or state "N/A". A sample of <Redacted B4> is not statistically significant enough to form the rationale for establishing a product expiration date. ...
Observation 13
Established laboratory control mechanisms are not followed.
Specifically:
I . You do not qualify each lot of <Redacted B4> cartridges before use for Bacterial endotoxin testing (BET) of drug products including B-Complex + Chromic Chloride 30 mL for injection, Ethanol for Injection 95%, Medroxyprogesterone Acetate 150 mg/ml for injection, and Sanacenia Purpurea 0.17 g/ml for injection.
2. Your procedure SOP QC-0092 Chromatography Column Receipt and Handling stipulates that a usage log shall be maintained for the HPLC column. However no log is currently in use for the column identified as a <Redacted B4> Serial # <Redacted B4> used for Sanacenia Purpurea Bulle Distillate and Sanacenia Purpurea O .17 g/ml for injection drug product HPLC Identity Assay and <Redacted B4> Potency Assay. While you indicated that a log will be kept for the next HPLC column you acquire, a log should also be kept for the current one to monitor the column throughout its lifecycle and anticipate the need for column maintenance or replacement.
3. You did not validate your <Redacted B4> test method for holding production <Redacted B4> over a specified time period for each applicable drug product. ...
Observation 14
Detenrminations of conformance to appropriate written specifications for acceptance are deficient in that they are not made for each lot within each shipment of components used in the manufacture, processing, packing or holding of drug products.
Specifically, your firm receives Sanacenia purpurea leaves for processing into bulk distillate and final drug product. The only documentation associated with each shipment of <Redacted B4> is an email from the <Redacted B4> supplier stating the weight of <Redacted B4> shipped. When you receive the <Redacted B4> , you weigh them, perform a visual inspection, and send a sample to a contract lab for <Redacted B4> identification. You do not test the incoming Sanacenia pupurea leaves for potential pesticide content. You also do not test your Sanacenia purpurea bulk distillate or final drug product for pesticide content.
Observation 15
Protective apparel is not worn as necessaiy to protect drug products from contamination.
Specifically, your procedure SOP # QA-0022 Traffic and Gowning Requirements, Effective Date: 11/08/2021 does not include requirements for personnel gowning to enter the ISO 8 room <Redacted B4> for preparation of equipment to enter the ISO 7 Room <Redacted B4> or to prepare process equipment and components for sterilization including aseptic filling tubing sets. On 03/23/2022, during your aseptic simulation for Static Preservation Solution <Redacted B4> filling of IV Bags, Lot # <Redacted B4>, we observed personnel outside the clean room in street clothes, except for shoe covers and exam gloves, wipe down bins with wipes and sterile <Redacted B4> then enter the ISO 8 room without additional gowning and repeat the wipe down. Additionally, we observed that the clean room technician retrieved the bins without performing a final sanitization wipe down of all the nested bins -only the <Redacted B4> bin surfaces received <Redacted B4> before entry to the ISO 7 clean room housing the ISO 5 classified BSC <Redacted B4> where aseptic operations are performed.
AM ENDMENT l
Observation 16
The labels of your outsourcing facility's drug products are deficient.
Specifically:
1. The labels of your outsourcing facility's drug products do not include information required by section 503 B( a )(10). Specifically, the following information is not found on your drug product labels:
a. The dosage form. Examples of your drug product labels that do not contain this information •B-Complex + Chromic Chloride
b. A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Examples of your drug product labels that do not contain this information: • Sanacenia Purpurea 0 .17 g/mL, 10 mL: The inactive ingredients are listed as salts and volatile bases of Sarraceniaceae (99%) and benzyl alcohol in <Redacted B4> (0. 7 5%) without reference to what salts and bases of Sanaceniaceae are included and at what proportion.
2.Route of administration.
Examples of drng product containers that do not contain this info1mation:
• SaITacenia Purpurea 0 .17 glmL, 10 mL; Medroxyprogesterone Acetate 150 mg/mL;
AM ENDMENT l
Observation 17
Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that is registered under section 510 as required by section 503B(a)(2)(C).
Specifically, you manufacture Sanacenia Pupurea 0.17 g/ml for injection finished drug product from the bulk drug substance Sanacenia Pupurea Bulk Distillate produced in your facility which is not registered under section 510 of the Act.
Inspection Jun 18, 2019 to Jul 23, 2019: 11 observations
- Firm on the cover
- US Specialty Formulations LLC, 116 Research Dr, Bethlehem, PA 18015-4731
- FEI number
- 3010680515
- Establishment type on the cover
- 503b Outsourcing Facility
- FDA district office on the cover
- US Customhouse Rm 900 200 Chestnut St Philadelphia, PA 19106
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard, actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically, processes used for the compounding and filling of any drug products produced by your firm have not been validated.
Drug products compounded and/or filled using non-validated processes include Betamethasone, Medroxy and Monsel's Paste.
Observation 2
Results of stability testing are not used in determining expiration dates.
Specifically,
a) Multivitamin lot 01 RH0413A was retested after having been expired for 5 months and issued a new label with an additional 6 month expiration date. Lot 0IRH0413A was filled on April 13, 2016 and issued an expiration date of October 13, 2016. On February 21, 2017 the expired product was relabeled as lot 01 RJ 1506A and issued an expiration date of November 3, 2017. The relabeled lot was released on February 27, 2017.
b) Expiration dating is not supported by stability data. For example:
Lot 0 1 RMI 504A, Ethanol was labeled with a 2 year expiration; stability data for this drug product is only available for 18 months.
Lot 0 l RMI 514A, Mons el' s Paste was labeled with a 3 year expiration; stability data for this drug product is only available for 18 months.
Lot 01RK1507A, Pyridoxine was labeled with a 1 year expiration; stability data for this drug product is only available for 9 months.
Lot 01RK1514A, Methylcobalamin was labeled with a 1 year expiration; stability data for this drug product is only available for 6 months.
Observation 3
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically, release testing for Sarapin is limited to testing for nitrogen content, benzyl alcohol, bacterial endotoxins and sterility. There is no test to quantify the concentration of active pharmaceutical ingredient. Sarapin fmished lot 01RM1502A was released on February 26, 2019 without a test to quantify active ingredient concentration.
Observation 4
Drug products failing to meet established specifications are not rejected.
Specifically, Lot 01RJ1522A(Strong Iodine Solution) and Lot 01RJ1534A(B-Complex w/ Chromic Chloride) were released after failing to meet established finished product specifications.
Strong Iodine Solution has an established release specification of <Redacted B4> Iodine concentration. Lot 01 RJ l 522A contained Ł 5. 9% Iodine concentration. Release specifications for Iodme concentration were changed to <Redacted B4> and the lot was released on August 17, 2017.
B-Complex w/ Chromic Chloride has an established release specification of l<Redacted B4> mg/mL Riboflavin and <Redacted B4> mlQI mg/mL Methylcobalamin. Lot 0IRJl534A contained 0.66 mg/mL Riboflavin and 0.42 mg/ML Methylcobalamin. The lot was released on November 2, 2017.
Observation 5
Written procedures for sampling and testing plans are not followed for each drug product.
Specifically, OOS retesting for Lot 0IRKl 517 A did not conform with fum's OOS procedure when it invalidated an OOS result. Firm procedure requires the sample be retest~ times to confirm results . Lot 01RK1517A Betamethasone was retested one time and subsequently released on September 27, 2018.
Observation 6
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
Specifically, test methods for the following finished product tests have not been validated:
~ Complex - Chromic Chloride potency • • •
B-Complex - Chronic Chloride potency Betamethasone potency Medroxyprogesterone potency
Methylcobalamin potency
Observation 7
Procedures prescribing a system for reprocessing batches to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics are not written.
Specifically, your firm has no procedure for reworldng products. Lot 01 RKl 523A, Betamethasone failed fmished product testing for betamethasone acetate concentration and was reworked without a procedure or protocol. The lot was released on March 28, 2019.
The investigation into the failed batch did not evaluate the quality impact of the rework procedure.
Observation 8
GMP training is not conducted on a continuing basis and with sufficient frequency to assure that employees remain familiar with COMP requirements applicable to them.
Specifically, no GMP training has been provided since 2016. Your frrm's training procedure does not require GMP training.
For example, John Issac, Executive Director of Quality performs batch review and release and has not received ongoing GMP training.
Observation 9
Appropriate controis are not exercised over computers or related systems to assure that changes in master production and control records or other records arc instituted only by authorized personnel.
Specifically, there is no quality review of your firm's laboratory software audit trail. The unreviewed audit trail contained aborted analysis on 4/24/2019, 5/8/2019 and 6/4/2019. To date there has been no deviation opened to assess potential product impact.
Observation 10
Clothing of personnel engaged in the manufacturing of drug products is not appropriate for the duties they perform.
Specifically, an employee formulating 8-Complex (Lot 0IRM1516A) extended their arms into the biological safety cabinet (ISO 5) beyond their sterile sleeve coverings.
Observation 11
The labels of your outsourcing facility's drug products are deficient.
Specifically, the following information is not found on your drug product labels:
A list of inactive ingredients identified by established name and the quantity or proportion of each ingredient. An example of your drug product label that does not contain this information is ethanol for injection 95% 67 mL MDV.
Inspection Aug 9, 2017 to Aug 29, 2017: 7 observations
- Firm on the cover
- , 116 Research Dr us Specialty Formulations LLC, Bethlehem, PA 18015-4731
- FEI number
- 3010680515
- Establishment type on the cover
- 503(b) Out sourcing Facility
- FDA district office on the cover
- US Customhouse Room 900 2nd & Chestnut St Philadelphia, PA 19106
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Clothing of personnel engaged in the manufacturing, processing and packing of drug products is not appropriate for the duties they perform.
Specifically,
(a) Gowning for aseptic operations are conducted in non-classified areas. The gowning area is not supplied with HEPA filtered air. Personnel apply sterile gowns, hairnets, foot covers, face masks, and non-sterile gloves in the non-classified gowning area. If proceeding into classified areas, personnel apply sterile gloves in the non-classified area of Lab <Redacted B4> If proceeding to work in the ISO 7 area with the ISO 5 <Redacted B4> personnel apply sterile sleeve covers in the non-classified Lab <Redacted B4> area.
b) An employee applying the metal crimping to stoppered vials of Pyridoxine (Lot# 01RJ1532A) in the (<Redacted B4> ISO 5) did not have their gown fully buttoned and their street clothes were exposed while working.
Observation 2
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
Your cleaning procedure has insufficient contact time for the use <Redacted B4> cleaning agent.
Additionally, your written procedure titled "Cleaning of classified areas" (PR-0003, Version 3.0) is deficient in that it:
(a) does not include instmctions for pre-cleaning (b) does not state the that disinfectants used in ISO 5 areas are required to be sterile (c) it does not state the recovery time required after the <Redacted B4> opened for cleaning.
THIS IS A REPEAT OBSERVATION FROM THE PREVIOUS INSPECTION
Observation 3
Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity ofthe drug product.
Specifically,
The surfaces of the lower shelves on two metal tables, one located in the ISO 7 and one in ISO 8 area of the cleanroom, were observed to be visibly msted.
The surface of these tables come in contact with processing materials, such as containers of product and equipment, as they proceed into the ISO 5 environment for aseptic processing operations.
Observation 4
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically,
You have not conducted testing ofthe preservative content or determined the effectiveness ofthe preservative in your Betamethasone Acetate 25mg in 10mL/Betamethasone Sodium Phosphate 40mg in
10mL sterile vials.
The following lot numbers of Betamethasone have been released:
Lot# Size 01RJ1516A <Redacted B4> vials
01RJ1524A <Redacted B4> vials
THIS IS A REPEAT OBSERVATION BUT RELATED A DIFFERENT PRODUCT.
Observation 5
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel. Specifically,
During inspection of the <Redacted B4> software (Version <Redacted B4> used to conduct assay testing with the <Redacted B4> the following was observed:
a. There was no login required for the computer operating system. b. Raw data files with assay test results could be deleted in the Windows operating system. c. The deletion of the raw data was not recorded in the system audit trail.
d. Three different people, including lab personnel and the Head of Operations, has administrator level privileges in the software.
Observation 6
Specifically,
Testing conducted by the frm's in-house laboratory are not reviewed by a second person to review the records for accuracy.
Observation 7
The container labels of your outsourcing facility's drug products are deficient.
The labels for some of your outsourcing facility's drug products do not include information required in section 503B(a)(10)(A).
Specifically,
1. The statement, "This is a compounded drug."
2. The dosage form and strength.
3. The statement of quantity or volume, as appropriate.
4. The inactive ingredients, identified by established name and the quantity or proportion of each ingredient.
Furthermore, the container for some of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B).
Specifically,
1. The information to facilitate adverse event reporting (www.fda.gov/medwatch and 1-800-FDA1088) is incorrectly stated.
1. The information to facilitate adverse event reporting (www.fda.gov/medwatch and 1-800-FDA1088) is incorrectly stated.
Examples of drug products that do not include this information on the label and/or container:
• 10mL Sarracenia Purpurea for Injection (Sarapin)
• 50mL Sarracenia Purpurea for Injection (Sarapin) • Pyrodoxine Hydiochloride 100 mg/mL
• Medioxyprogesterone 150 mg ...
Linked 483s whose text is not shown
- Jan 14, 2026: FDA document 190899: its numbered observations could not be read reliably from the PDF text.
- Jul 17, 2015: FDA document 92186: the PDF is a scanned image with no readable text.
State board of pharmacy records
State board of pharmacy records for Pennsylvania are not checked: the Department of State’s license lookup (PALS) did not respond on November 6, 2026, and when tried again on November 7, 2026 it answered with a script-driven search application, which this index does not use; its monthly discipline reports are listed only through a script-driven search page.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0000034 | Outsourcing Facility-Distributor | US Specialty Formulations, LLC | ALLENTOWN, PA | Active |
FDA’s 503B list
- US Specialty Formulations LLC, Allentown, PA: last inspection Jan 14, 2026, Form 483 at that inspection: Yes, action FDA lists: Open.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Delaware Division of Professional Regulation license file
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.